Recombinant Human HLA-A*02:01&B2M&Vaccinia Virus(VLYNGVNYL) Monomer Protein (HEK293)，Avi & His

The study of HLA-A*02:01 and its interaction with the β2-microglobulin (B2M) is pivotal in understanding immune responses, particularly in the context of viral infections. HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules, crucial for presenting peptides derived from intracellular pathogens, such as viruses, to CD8+ cytotoxic T lymphocytes. The incorporation of viral peptides, such as the YLAKLTALV epitope derived from the Vaccinia virus, into the HLA-A*02:01 structure significantly enhances our understanding of how the immune system recognizes and combats viral infections. Research on monomeric recombinant proteins of HLA-A*02:01 in complex with B2M and the Vaccinia virus peptide provides valuable insights into the molecular mechanisms of immune recognition. This knowledge is vital for developing effective vaccines and immunotherapies against viral diseases, leveraging the strength of the adaptive immune system to elicit targeted responses. Moreover, studying the stability and conformation of these complexes expands our comprehension of peptide-MHC interactions and informs therapeutic strategies aimed at manipulating immune responses in various contexts, including cancer and infectious diseases. The characterization of the HLA-A*02:01/B2M/Vaccinia virus (YLAKLTALV) monomer not only deepens our fundamental understanding of T-cell activation but also holds promise for clinical applications in designing more effective immunotherapeutic agents.